Antiviral Action of Curcumin Encapsulated in Nanoemulsion against Four Serotypes of Dengue Virus

Author(s): Najwa Nabila, Nadia Khansa Suada, Dionisius Denis, Benediktus Yohan, Annis Catur Adi, Anna Surgean Veterini, Atsarina Larasati Anindya, R. Tedjo Sasmono, Heni Rachmawati*.

Journal Name: Pharmaceutical Nanotechnology

Volume 8 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Curcumin has been used as a traditional medicine showing antiinflammatory, antimicrobial, and antiviral properties. Despite the promising potentials, curcumin-based drug development is hindered due to its poor solubility and cell uptake.

Objective: This study aims to produce curcumin nanoemulsion (nanocurcumin) and evaluate its physical characteristics and in vitro cell cytotoxicity and antiviral activity against dengue virus (DENV).

Methods: Nanocurcumin was generated by self-nanoemulsion technique. Cytotoxicity was determined using MTT assay in A549 cell line. Anti-DENV properties were determined by calculation of inhibitory concentration 50 (IC50) and plaque assay.

Results: The resulting nanoemulsion showed uniform droplet size distribution with the average droplet size of 40.85 ± 0.919 nm. Nanocurcumin exhibited higher cell cytotoxicity compared to curcumin solution and may be explained by better cell uptake. Nanocurcumin treatment suppressed DENV growth, although no significant difference observed compared to the curcumin solution counterpart. Greater virus reduction was observed for DENV-1 and DENV-2.

Conclusion: The synthesis of nanocurcumin improved curcumin physicochemical properties with potential as antiviral against DENV.

Keywords: A549 cell line, antiviral activity, cellular uptake, Curcumin, dengue virus, nanoemulsion.

[1]
Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11(3): 480-96.
[http://dx.doi.org/10.1128/CMR.11.3.480] [PMID: 9665979]
[2]
Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496(7446): 504-7.
[http://dx.doi.org/10.1038/nature12060] [PMID: 23563266]
[3]
Karyanti MR, Uiterwaal CSPM, Kusriastuti R, et al. The changing incidence of dengue haemorrhagic fever in Indonesia: a 45-year registry-based analysis. BMC Infect Dis 2014; 14: 412.
[http://dx.doi.org/10.1186/1471-2334-14-412] [PMID: 25064368]
[4]
Martina BEE, Koraka P, Osterhaus ADME. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009; 22(4): 564-81.
[http://dx.doi.org/10.1128/CMR.00035-09] [PMID: 19822889]
[5]
Abd Kadir SL, Yaakob H, Mohamed Zulkifli R. Potential anti-dengue medicinal plants: a review. J Nat Med 2013; 67(4): 677-89.
[http://dx.doi.org/10.1007/s11418-013-0767-y] [PMID: 23591999]
[6]
Lestari MLAD, Indrayanto G. Curcumin. Profiles Drug Subst Excip Relat Methodol 2014; 39: 113-204.
[http://dx.doi.org/10.1016/B978-0-12-800173-8.00003-9] [PMID: 24794906]
[7]
Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int 2014; 2014: 186864
[PMID: 24877064]
[8]
Anggakusuma, Colpitts CC, Schang LM, et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014; 63: 1137-49.
[9]
Ferreira VH, Nazli A, Dizzell SE, Mueller K, Kaushic C. The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. PLoS One 2015; 10(4): e0124903
[http://dx.doi.org/10.1371/journal.pone.0124903] [PMID: 25856395]
[10]
Avasarala S, Zhang F, Liu G, Wang R, London SD, London L. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLoS One 2013; 8(2): e57285
[http://dx.doi.org/10.1371/journal.pone.0057285] [PMID: 23437361]
[11]
Padilla-S L, Rodríguez A, Gonzales MM, Gallego-G JC, Castaño-O JC. Inhibitory effects of curcumin on dengue virus type 2-infected cells in vitro. Arch Virol 2014; 159(3): 573-9.
[http://dx.doi.org/10.1007/s00705-013-1849-6] [PMID: 24081825]
[12]
Balasubramanian A, Pilankatta R, Teramoto T, et al. Inhibition of dengue virus by curcuminoids. Antiviral Res 2019; 162: 71-8.
[http://dx.doi.org/10.1016/j.antiviral.2018.12.002] [PMID: 30529358]
[13]
Chen TY, Chen DY, Wen HW, et al. Inhibition of enveloped viruses infectivity by curcumin. PLoS One 2013; 8(5): e62482
[http://dx.doi.org/10.1371/journal.pone.0062482] [PMID: 23658730]
[14]
Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82(2): 373-428.
[http://dx.doi.org/10.1152/physrev.00027.2001] [PMID: 11917093]
[15]
Rachmawati H, Soraya IS, Kurniati NF, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm 2016; 84(1): 131-40.
[http://dx.doi.org/10.3797/scipharm.ISP.2015.05] [PMID: 27110504]
[16]
Rachmawati H, Budiputra DK, Mauludin R. Curcumin nanoemulsion for transdermal application: formulation and evaluation. Drug Dev Ind Pharm 2015; 41(4): 560-6.
[http://dx.doi.org/10.3109/03639045.2014.884127] [PMID: 24502271]
[17]
Haryanto S, Hayati RF, Yohan B, et al. The molecular and clinical features of dengue during outbreak in Jambi, Indonesia in 2015. Pathog Glob Health 2016; 110(3): 119-29.
[http://dx.doi.org/10.1080/20477724.2016.1184864] [PMID: 27215933]
[18]
Aryati A, Trimarsanto H, Yohan B, Wardhani P, Fahri S, Sasmono RT. Performance of commercial dengue NS1 ELISA and molecular analysis of NS1 gene of dengue viruses obtained during surveillance in Indonesia. BMC Infect Dis 2013; 13: 611.
[http://dx.doi.org/10.1186/1471-2334-13-611] [PMID: 24571329]
[19]
Wardhani P, Aryati A, Yohan B, et al. Clinical and virological characteristics of dengue in Surabaya, Indonesia. PLoS One 2017; 12(6)e0178443
[http://dx.doi.org/10.1371/journal.pone.0178443] [PMID: 28575000]
[20]
Yohan B, Kendarsari RI, Mutia K, Bowolaksono A, Harahap AR, Sasmono RT. Growth characteristics and cytokine/chemokine induction profiles of dengue viruses in various cell lines. Acta Virol 2014; 58(1): 20-7.
[http://dx.doi.org/10.4149/av_2014_01_20] [PMID: 24717025]
[21]
Baer A, Kehn-Hall K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. J Vis Exp 2014.: e52065
[22]
Rachmawati H. Curcumin Nanoforms Promise Better Therapeutic Values. Int J Res Pharm Sci 2013; 4: 211-20.
[23]
Rachmawati H, Meylina L, Rahma A, Sumirtapura YC. Size-dependent of oil droplet of curcumin nanoemulsion on the in vivo release kinetic of curcumin after oral and intravenous administration in animal model. Adv Sci Eng Med 2014; 6: 959-64.
[http://dx.doi.org/10.1166/asem.2014.1582]
[24]
Kwon HJ, Heo EJ, Kim YH, et al. Development and evaluation of poorly water-soluble celecoxib as solid dispersions containing nonionic surfactants using fluidized-bed granulation. Pharmaceutics 2019; 11(3): 136.
[http://dx.doi.org/10.3390/pharmaceutics11030136] [PMID: 30897776]
[25]
Li Y, Zhang S, Geng JX, Hu XY. Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev 2013; 14(8): 4599-602.
[http://dx.doi.org/10.7314/APJCP.2013.14.8.4599] [PMID: 24083709]
[26]
Wang A, Wang J, Zhang S, Zhang H, Xu Z, Li X. Curcumin inhibits the development of non-small cell lung cancer by inhibiting autophagy and apoptosis. Exp Ther Med 2017; 14(5): 5075-80.
[http://dx.doi.org/10.3892/etm.2017.5172] [PMID: 29201217]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 1
Year: 2020
Page: [54 - 62]
Pages: 9
DOI: 10.2174/2211738507666191210163408
Price: $65

Article Metrics

PDF: 21
HTML: 4